N-Acetyl Semax Amidate
NootropicNA Semax Amidate — Synthetic Peptide
Overview
N-Acetyl Semax Amidate is the most chemically modified form of the Semax peptide backbone (Met-Glu-His-Phe-Pro-Gly-Pro), incorporating N-terminal acetylation and C-terminal amidation. Semax itself is a Russian-approved neuropeptide derived from ACTH(4-10) with an established clinical record for stroke and cognitive disorders. The acetyl and amidate modifications represent rational medicinal chemistry optimizations that are widely applied to improve peptide pharmacokinetics.
N-Acetyl Semax Amidate has no independent published clinical research. Its evidence base is entirely derived from Semax studies. In the nootropic research community it is colloquially considered the "strongest" Semax variant due to the combined stability enhancements, though this assumption is not validated by direct comparative studies. It is sold exclusively as a research peptide with no regulatory approval.
Mechanism of Action
N-Acetyl Semax Amidate engages the same mechanistic pathways as Semax, with potentially enhanced CNS bioavailability:
**BDNF/NGF upregulation** is the primary nootropic mechanism. Semax rapidly elevates BDNF and its receptor TrkB in the hippocampus, driving synaptic plasticity, long-term potentiation, and neuronal survival. This neurotrophic effect is considered the foundation of its cognitive-enhancing and neuroprotective properties.
**Melanocortin receptor modulation:** The ACTH-derived sequence engages MC4 and MC5 receptors, influencing dopaminergic and serotonergic transmission without the full hormonal effects of ACTH.
**Immune and vascular gene modulation:** Semax has documented effects on hundreds of genes related to immune response, neuroinflammation, and vascular function during ischemia, providing its neuroprotective profile beyond simple neurotrophic upregulation.
**Enhanced metabolic stability:** N-terminal acetylation blocks aminopeptidase N cleavage; C-terminal amidation blocks carboxypeptidase activity and mimics the endogenous amide bond present in naturally occurring bioactive peptides. Together these modifications protect both termini from the primary enzymatic degradation routes, extending plasma half-life and potentially improving CNS exposure relative to standard Semax.
Research Dosing
The dual terminal modification (N-acetyl + C-amidate) is theorized to produce greater enzymatic stability and BBB penetration than standard Semax. Effective dose may be lower than Semax due to increased potency. No human clinical data exists specific to this modification.
Subcutaneous route used in research settings. Higher systemic bioavailability than intranasal but less convenient. All protocols extrapolated from Semax research.
Research data only. These dosing ranges are derived from published studies, primarily in animal models. This is not medical advice. No peptide discussed on this site is approved for human therapeutic use unless otherwise noted.
Published Studies
Semax in prevention of disease progress and development of exacerbations in patients with cerebrovascular insufficiency
Gusev EI, Skvortsova VI, Miasoedov NF, et al. — Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 2005
Human clinical trial of the parent compound Semax in acute ischemic stroke (6mg/day intranasal, 5 days) demonstrating reduced neurological deficit severity and improved functional outcomes. Forms the primary human evidence base from which N-Acetyl Semax Amidate is mechanistically extrapolated.
PMID: 15792140 →AnimalThe peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis
Dmitrieva VG, Stavchansky VV, Povarova OV, et al. — BMC Genomics, 2014
Genome-wide transcriptional analysis showing Semax modulates hundreds of genes involved in immune response, angiogenesis, and vascular function during focal brain ischemia. N-Acetyl Semax Amidate is presumed to engage the same gene networks with potentially greater efficiency due to enhanced enzymatic stability.
PMID: 24661604 →AnimalEffect of semax on the temporal dynamics of brain-derived neurotrophic factor and nerve growth factor gene expression in the rat hippocampus and frontal cortex
Agapova TIu, Agniullin IaV, Silachev DN, et al. — Molekuliarnaia Genetika, Mikrobiologiia i Virusologiia, 2008
Demonstrated BDNF and NGF upregulation in rat hippocampus and cortex following Semax administration, supporting the primary nootropic and neuroprotective mechanism shared by all Semax analogs including N-Acetyl Semax Amidate.
PMID: 18756821 →